补阳还五汤改善低氧性肺动脉高压血管重塑中的作用及其机制研究
The Role and Mechanisms of Bu Yang Huan Wu Decoction in Improving Vascular Remodeling in Hypoxic Pulmonary Hypertension
DOI: 10.12677/acm.2026.1652139, PDF,    科研立项经费支持
作者: 平松鹤, 唐任绮, 单红光:绍兴大学医学院,浙江 绍兴;叶 涵:浙江大学医学院,浙江 杭州;何 梦*:绍兴市人民医院(绍兴大学附属第一医院)呼吸与危重症医学科,浙江 绍兴
关键词: 补阳还五汤肺动脉高压自噬代谢肺血管重塑Bu Yang Huan Wu Decoction Pulmonary Hypertension Autophagy Metabolism Pulmonary Vascular Remodeling
摘要: 目的:探讨补阳还五汤在低氧性肺动脉高压(HPH)中的干预作用及其潜在机制,评估其对肺血管重塑、肺动脉压力、右心室肥厚、自噬与凋亡等方面的影响。方法:采用低氧诱导的HPH小鼠模型与原代肺动脉平滑肌细胞(PASMCs)模型,结合HE染色、右心导管法、右心室肥厚指数(RVHI)、TUNEL染色、Western blot、划痕实验与LC3免疫荧光等技术,系统评估补阳还五汤的干预效果。研究通过观察肺血管重塑、肺动脉压力、右心室功能、自噬与凋亡的分子机制,探讨其作用途径。结果:补阳还五汤显著改善低氧诱导的肺血管重塑,减少肺动脉压力和右心室肥厚,且具有剂量依赖性。低剂量组(BHD-L)和高剂量组(BHD-H)均能抑制PASMCs的异常迁移、减少细胞凋亡,并调节自噬通路,恢复自噬稳态。高剂量组的干预效果更加显著,提示其对HPH的治疗具有潜力。结论:补阳还五汤通过多途径调节PASMCs的代谢、自噬、凋亡与迁移行为,显著改善HPH的病理变化。该方剂为HPH的治疗提供了新的安全、经济且有效的治疗策略,并为中医药在肺血管疾病中的现代化应用提供了科学依据。
Abstract: Objective: This paper aims to investigate the effects and mechanisms of Bu Yang Huan Wu Decoction in hypoxic pulmonary hypertension (HPH), focusing on pulmonary vascular remodeling, pulmonary arterial pressure, right ventricular hypertrophy, autophagy, and apoptosis. Methods: Hypoxia-induced HPH mouse and PASMC models were established. HE staining, right heart catheterization, RVHI, TUNEL, Western blot, scratch assay, and LC3 immunofluorescence were used to assess the effects of Bu Yang Huan Wu Decoction and explore related mechanisms. Results: Bu Yang Huan Wu Decoction significantly alleviated pulmonary vascular remodeling, reduced pulmonary arterial pressure and right ventricular hypertrophy, and showed dose-dependent effects. Both the low-dose group (BHD-L) and the high-dose group (BHD-H) can inhibit the abnormal migration of pulmonary artery smooth muscle cells (PASMCs), reduce cell apoptosis, regulate the autophagy pathway, and restore autophagy homeostasis. The intervention effect of the high-dose group is more significant, suggesting its potential for the treatment of hypoxic pulmonary hypertension (HPH). Conclusion: Bu Yang Huan Wu Decoction improves HPH pathological changes by regulating PASMC autophagy, apoptosis, metabolism, and migration. This prescription offers a novel, safe, cost-effective, and efficient treatment strategy for HPH, and provides a scientific basis for the modern application of traditional Chinese medicine in pulmonary vascular diseases.
文章引用:平松鹤, 唐任绮, 单红光, 叶涵, 何梦. 补阳还五汤改善低氧性肺动脉高压血管重塑中的作用及其机制研究[J]. 临床医学进展, 2026, 16(5): 3201-3208. https://doi.org/10.12677/acm.2026.1652139

参考文献

[1] Ghofrani, H., Gomberg-Maitland, M., Zhao, L. and Grimminger, F. (2025) Mechanisms and Treatment of Pulmonary Arterial Hypertension. Nature Reviews Cardiology, 22, 105-120. [Google Scholar] [CrossRef] [PubMed]
[2] Latimer, K., Layne, M. and Payne, M. (2024) Pulmonary Hypertension. American Family Physician, 110, 183-191.
[3] GBD 2021 Stroke Risk Factor Collaborators (2024) Global, Regional, and National Burden of Stroke and Its Risk Factors, 1990-2021: A Systematic Analysis for the Global Burden of Disease Study 2021. The Lancet Neurology, 23, 973-1003.
[4] GBD 2021 Pulmonary Arterial Hypertension Collaborators (2025) Global, Regional, and National Burden of Pulmonary Arterial Hypertension, 1990-2021: A Systematic Analysis for the Global Burden of Disease Study 2021. The Lancet Respiratory Medicine, 13, 69-79.
[5] SEC Working Group for the 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension and SEC Guidelines Committee (2023) Comments on the 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Revista Española de Cardiología (English Edition), 76, 294-300.
[6] Cao, Y., Yao, W., Yang, T., Yang, M., Liu, Z., Luo, H., et al. (2024) Elucidating the Mechanisms of Buyang Huanwu Decoction in Treating Chronic Cerebral Ischemia: A Combined Approach Using Network Pharmacology, Molecular Docking, and in Vivo Validation. Phytomedicine, 132, Article ID: 155820. [Google Scholar] [CrossRef] [PubMed]
[7] Mo, J., Liao, W., Du, J., Huang, X., Li, Y., Su, A., et al. (2024) Buyang Huanwu Decoction Improves Synaptic Plasticity of Ischemic Stroke by Regulating the cAMP/PKA/CREB Pathway. Journal of Ethnopharmacology, 335, Article ID: 118636. [Google Scholar] [CrossRef] [PubMed]
[8] Huang, H., Liu, S., Wu, J., Zhu, J., Xu, J., Yu, S., et al. (2025) Buyang Huanwu Decoction Alleviates Ischemic Stroke Injury by Inhibiting Ferroptosis via the Nrf2/gpx4 Pathway. Drug Design, Development and Therapy, 19, 2285-2305. [Google Scholar] [CrossRef] [PubMed]
[9] Colon Hidalgo, D., Elajaili, H., Suliman, H., George, M.P., Delaney, C. and Nozik, E. (2022) Metabolism, Mitochondrial Dysfunction, and Redox Homeostasis in Pulmonary Hypertension. Antioxidants, 11, Article No. 428. [Google Scholar] [CrossRef] [PubMed]
[10] Zhang, W., Liu, B., Wang, Y., Zhang, H., He, L., Wang, P., et al. (2022) Mitochondrial Dysfunction in Pulmonary Arterial Hypertension. Frontiers in Physiology, 13, Article ID: 1079989. [Google Scholar] [CrossRef] [PubMed]
[11] D’Alessandro, A., El Kasmi, K.C., Plecitá-Hlavatá, L., Ježek, P., Li, M., Zhang, H., et al. (2018) Hallmarks of Pulmonary Hypertension: Mesenchymal and Inflammatory Cell Metabolic Reprogramming. Antioxidants & Redox Signaling, 28, 230-250. [Google Scholar] [CrossRef] [PubMed]
[12] Riou, M., Enache, I., Sauer, F., Charles, A. and Geny, B. (2023) Targeting Mitochondrial Metabolic Dysfunction in Pulmonary Hypertension: Toward New Therapeutic Approaches? International Journal of Molecular Sciences, 24, Article No. 9572. [Google Scholar] [CrossRef] [PubMed]
[13] Geng, Y., Hu, Y., Zhang, F., Tuo, Y., Ge, R. and Bai, Z. (2023) Mitochondria in Hypoxic Pulmonary Hypertension, Roles and the Potential Targets. Frontiers in Physiology, 14, Article ID: 1239643. [Google Scholar] [CrossRef] [PubMed]
[14] Culley, M.K. and Chan, S.Y. (2018) Mitochondrial Metabolism in Pulmonary Hypertension: Beyond Mountains There Are Mountains. Journal of Clinical Investigation, 128, 3704-3715. [Google Scholar] [CrossRef] [PubMed]
[15] Deng, X., Qiu, P., Li, X., Hu, Y., Que, Q., Zhang, K., et al. (2025) Potential of Sivelestat for Pulmonary Arterial Hypertension Treatment: Network Pharmacology-Based Target Identification and Mechanistic Exploration. Drug Design, Development and Therapy, 19, 4123-4138. [Google Scholar] [CrossRef] [PubMed]
[16] Wu, P., Xie, X., Chen, M., Sun, J., Cai, L., Wei, J., et al. (2021) Elucidation of the Mechanisms and Molecular Targets of Qishen Yiqi Formula for the Treatment of Pulmonary Arterial Hypertension Using a Bioinformatics/Network Topology-Based Strategy. Combinatorial Chemistry & High Throughput Screening, 24, 701-715. [Google Scholar] [CrossRef] [PubMed]